罗莫佐单抗对LRP5、LRP6或WNT1基因变异患者有效
该研究基于27例携带LRP5/6或WNT1基因变异的绝经后女性的临床常规数据(共33患者年),比较了罗莫佐单抗与抗骨吸收治疗或未治疗的效果。结果显示罗莫佐单抗组腰椎面积骨密度增幅显著高于其他组,并伴随胫骨小梁骨密度及骨形成标志物升高。提示罗莫佐单抗可能成为此类基因定义骨丢失的潜在治疗选择。
要点
- 罗莫佐单抗组腰椎aBMD增幅(+15.74%±7.63%)显著优于抗骨吸收组(+3.97%±4.71%)和未治疗组(-0.12%±5.02%)。
- 罗莫佐单抗组胫骨小梁骨密度和骨质量增加,6个月时骨碱性磷酸酶升高(+3.08±2.21 µg/L vs 抗骨吸收组-3.36±8.044 µg/L,p=0.026)。
- 罗莫佐单抗可能作为LRP5/6或WNT1杂合变异患者的特异性治疗,但需更大样本研究验证。
核心结论
- 罗莫佐单抗在携带LRP5/6或WNT1基因杂合变异的绝经后女性中有效,且优于现有抗骨吸收治疗。
研究设计与样本
- 基于27例携带LRP5/6或WNT1基因杂合有害或明确风险等位变异(ACMG 2-5类)的绝经后女性临床常规数据,共33患者年,分为未治疗组12例、抗骨吸收组11例和罗莫佐单抗组10例。
主要发现
- 罗莫佐单抗组腰椎面积骨密度变化为+15.74%±7.63%,显著高于抗骨吸收组+3.97%±4.71%和未治疗组-0.12%±5.02%(p<0.001)。
- 罗莫佐单抗组胫骨小梁骨密度和骨质量增加,6个月时骨碱性磷酸酶变化为+3.08 µg/L±2.21 µg/L,抗骨吸收组为-3.36 µg/L±8.044 µg/L(p=0.026)。
临床怎么用
- 对于携带LRP5/6或WNT1基因变异的绝经后骨质疏松患者,罗莫佐单抗可考虑作为治疗选择。
局限性
- 样本量小(27例),需更大队列研究验证,尤其需关注双等位基因功能丧失变异患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Romosozumab has proven efficacy in postmenopausal osteoporosis, but data in LRP5/6 or WNT1 variant carriers are scarce. In 33 patient-years of women carrying such variants, romosozumab improved BMD and bone formation more than antiresorptives or no treatment. These findings suggest romosozumab as a potential therapy for genetically defined bone loss. PURPOSE: The sclerostin inhibitor romosozumab is an osteoanabolic drug that enhances the canonical Wnt-β-catenin pathway. While its efficacy in postmenopausal osteoporosis is known, clinical data on the use of romosozumab in patients with variants in the LRP5, LRP6, or WNT1 gene affecting this pathway remain limited. METHOD: We present clinical routine data of 33 patient-years in 27 postmenopausal women with heterozygous deleterious or established risk alleles variants (ACMG class 2-5) in the LRP5/6 or WNT1 gene, using dual-energy X-ray absorptiometry (DXA), high-resolution peripheral quantitative computed tomography (HR-pQCT), and laboratory parameters. Among these, 12 were treated with vitamin D and calcium only (NoT), 11 with antiresorptive therapy (AR), and 10 with romosozumab (ROMO). RESULTS: Patients treated with romosozumab showed significantly greater gains in areal bone mineral density (aBMD) compared to others (lumbar spine-NoT = -0.12% ± 5.02%, AR = + 3.97% ± 4.71%, ROMO = + 15.74% ± 7.63%, p < 0.001 for ROMO vs. AR and vs. NoT). This was accompanied by an increase in trabecular bone density and mass in the tibia, as well as elevated bone formation markers such as bone alkaline phosphatase after 6 months (AR = -3.36 µg/L ± 8.044 µg/L vs. ROMO = + 3.08 µg/L ± 2.21 µg/L, p = 0.026). Our findings indicate that romosozumab is effective in patients with heterozygous variants in the LRP5/6 or WNT1 gene. Here, romosozumab was superior to established antiresorptive treatments. CONCLUSION: Thus, romosozumab might be a specific treatment for these patients. However, further studies are needed with larger patient cohorts and in particular with regard to biallelic loss-of-function variants in the LRP 5/6 or WNT1 gene.
引用
- von Brackel FN, Dehne N, Kornak U, et al. Romosozumab is effective in patients with variants in LRP5, LRP6, or WNT1. Osteoporos Int. 2026. PMID: 41813941. doi:10.1007/s00198-026-07932-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。